DNER and glioblastoma: Extensive pre-clinical studies have shown that BET inhibitors, including JQ1,317,340 OTX015 (MK-8628 or birabresib),341 and I-BET151,312,313 reduce glioblastoma cell proliferation, inhibit cell cycle progression, and reduce tumour growth in vivo.